In wake of safe­ty scare, Mer­ck scraps month­ly PrEP plans for lead HIV drug — while march­ing ahead with re­vised clin­i­cal plans

Mer­ck is throw­ing in the tow­el on its lead can­di­date for a long-act­ing pre-ex­po­sure pro­phy­lax­is (PrEP) for HIV af­ter months of grap­pling with safe­ty con­cerns …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER